

# Off-pump vs on-pump surgery in patients with stable coronary artery disease

<b>Submission date</b> 21/02/2008	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 10/03/2008	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 20/12/2022	<b>Condition category</b> Circulatory System	<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Prof Whady Hueb

**Contact details**  
Av. Dr. Eneas Carvalho Aguiar 44 AB  
Sala 114  
Sao Paulo  
Brazil  
05403000

## Additional identifiers

**EudraCT/CTIS number**

**IRAS number**

**ClinicalTrials.gov number**

**Secondary identifying numbers**  
1926/01/114

## Study information

**Scientific Title**

A randomised comparative study of patients undergoing myocardial revascularisation with or without cardiopulmonary bypass surgery

**Acronym**

MASS III

**Study objectives**

The aim of the MASS III Trial is to compare medical effectiveness, safety, cerebral injury, quality of life, cost-effectiveness of coronary surgery with (on-pump) or without (off-pump) cardiopulmonary bypass.

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Institutional Review Board (Comissão de Ética para Análise de Projetos de Pesquisa - CAPPesq) approved on 19/10/2001.

**Study design**

Randomised controlled comparative trial

**Primary study design**

Interventional

**Secondary study design**

Randomised controlled trial

**Study setting(s)**

Not specified

**Study type(s)**

Treatment

**Participant information sheet**

Not available in web format, please use the contact details below to request a patient information sheet

**Health condition(s) or problem(s) studied**

Coronary artery disease

**Interventions**

Trial operators were required to perform optimum coronary revascularisation in accordance with the current best practices. The surgery was performed by physicians experienced in both on-pump and off-pump bypass surgery techniques. Surgical access to the heart was through a standard median sternotomy in all cases. All incisions and closure techniques were the same for both groups, limiting variability and maintaining blinding of group assignment for patients, family and cardiologists. A cell saver reservoir (COBE Cardiovascular, Inc., USA) was spun down and returned to all patients when the quantity was sufficient.

Off-pump strategies: Off-pump surgery used the Octopus stabiliser described in detail elsewhere. In brief, the distal ends of the two suction arms of the stabiliser are placed on the

beating heart on both sides of the target coronary artery. The proximal parts are fixed to the operating table. Through the application of negative pressure, the target area of the heart is sufficiently immobilised to allow the safe construction of the anastomosis of the graft with the recipient artery.

On-pump technique: Conventional coronary artery surgery with cardiopulmonary bypass was accomplished with every effort to minimize the impact of cardiopulmonary bypass. Patients without diabetes received 1 gram of hydrocortisone sodium succinate (SoluCortef®, Pharmacia & Upjohn Co., USA) intravenously before of anesthesia. This procedure will be made only in the on-pump technique.

## **Intervention Type**

Other

## **Phase**

Not Specified

## **Primary outcome measure**

The following will be assessed at discharge and 5-year follow-up:

1. Incidence of cardiovascular mortality
2. Cerebrovascular accident
3. Non-fatal myocardial infarction
4. Refractory angina requiring revascularisation

## **Secondary outcome measures**

The following were assessed at discharge and at 5-year follow-up:

1. Non-cardiac mortality
2. Presence and severity of angina
3. Quality of life, using the 36-item Short Form health survey (SF-36)
4. Cost-effectiveness

## **Overall study start date**

31/01/2002

## **Completion date**

31/01/2010

# **Eligibility**

## **Key inclusion criteria**

1. Male or female, age 18 years or older
2. Patients with stable angina pectoris and/or documented ischemia due to multivessel disease and preserved ventricular function
3. Angiographically confirmed multivessel coronary artery disease (CAD) with  $\geq 70\%$  lesions in at least two major epicardial vessels and at least two separate coronary artery territories (LAD, LCX and RCA)
4. Patients who are eligible for coronary surgery both with and without cardiopulmonary bypass circuit
5. Willing to comply with all follow-up study visits
6. Signed and received a copy of the informed consent

Note: Non-significant left main stenoses can be included

**Participant type(s)**

Patient

**Age group**

Adult

**Lower age limit**

18 Years

**Sex**

Both

**Target number of participants**

311

**Key exclusion criteria**

1. Age under 18 years
2. Severe congestive heart failure, New York Heart Association (NYHA) Class III or IV, or pulmonary edema
3. Prior valve replacement or coronary artery bypass graft (CABG) surgery
4. Prior percutaneous coronary intervention (PCI) with stent implantation within 6 months
5. Prior stroke within 6 months or patients with stroke that occurred more than 6 months ago with significant residual neurological involvement, as reflected in a Rankin score  $\geq 1$
6. Need for concomitant major surgery e.g. valve replacement, resection ventricular aneurysm, congenital heart disease vascular surgery of the carotid artery, or thoracic-abdominal aorta
7. Concomitant medical disorders making clinical follow-up at least 5 years unlikely or impossible e.g. neoplastic, hepatic, or other severe disease
8. Q-wave myocardial infarction in the previous 6 weeks
9. Hemorrhagic diathesis or hypercoagulability
10. Thoracic deformations technically precluding surgery without extracorporeal circulation
11. Unable to give informed consent

**Date of first enrolment**

31/01/2002

**Date of final enrolment**

31/01/2010

**Locations****Countries of recruitment**

Brazil

**Study participating centre**

**Av. Dr. Eneas Carvalho Aguiar 44 AB**  
Sao Paulo  
Brazil  
05403000

## **Sponsor information**

### **Organisation**

Zerbini Foundation (Fundação Zerbini) (Brazil)

### **Sponsor details**

Av. Dr. Eneas Carvalho Aguiar 44 AB  
Sala 114  
Sao Paulo  
Brazil  
05403-000

### **Sponsor type**

Charity

### **Website**

<http://www.incor.usp.br>

### **ROR**

<https://ror.org/003c2h870>

## **Funder(s)**

### **Funder type**

Charity

### **Funder Name**

Zerbini Foundation (Fundacao Zerbini) (Brazil)

## **Results and Publications**

### **Publication and dissemination plan**

Not provided at time of registration

### **Intention to publish date**

### **Individual participant data (IPD) sharing plan**

Not provided at time of registration

### IPD sharing plan summary

Not provided at time of registration

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	05/08/2014		Yes	No
<a href="#">Results article</a>	results	01/03/2015		Yes	No
<a href="#">Results article</a>	Long-term analysis	19/12/2022	20/12/2022	Yes	No